CTLA4 and esophageal cancer: sCTLA-4 was evaluated as a prognostic factor in lung and esophageal cancers, demonstrating that increased post-therapy levels (chemotherapy or radiochemotherapy) correlated with longer OS and PFS, suggesting that this soluble factor may block the classic immunosuppressive activity of CTLA-4 [23].